Anvita Sinha, MD
Urology · Fairfield
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- Not verified
- Not the same as out of network.
- Offices
- 3
Offices
3 locations · Northbay Physicians Surgery Center, LLC · Northbay Health Medical Foundation · County of Santa Clara
Hospitals listed: Santa Clara Valley Medical Center. That is not proof they admit you there this week.
Plan participation
Not verified
We could not verify current plan participation for this doctor. This does not mean they are out of network. Call Dr. Sinha’s office to ask if they take your plan before you enroll.
California Medical Board record
Licence G144001 · Current
Licensed to practise in California · since 2016 · expires 2028-03-31 · University of Michigan Medical School.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
Hospitals they work in
1 hospital
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- Santa Clara Valley Medical CenterSan Jose, CAAcute Care Hospital · Government - Local · Has an emergency department · Birthing-friendlyPart of Santa Clara Valley Health and Hospital System, which runs 3 hospitalsPatients rate it 3 of 5 · 70% would definitely recommend itOverall rating: 2 of 5 starsWorse than the national rate — SSI - Colon Surgery: 2.572, Oct 2024 – Sep 2025Better than the national rate — Central Line Associated Bloodstream Infection (ICU + select Wards): 0.563, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.256, Oct 2024 – Sep 2025Better than the national rate — MRSA Bacteremia: 0.369, Oct 2024 – Sep 2025
See every measure and the patient survey for Santa Clara Valley Medical Center
Behind the star rating — Deaths: 2 better, 6 the same, 0 worse of 8 measures. Safety: 2 better, 5 the same, 1 worse of 8 measures. Readmissions: 0 better, 10 the same, 1 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| SSI - Colon SurgeryInfections | 2.572 | Worse | Oct 2024 – Sep 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.563 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.256 | Better | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.369 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.25 (0.3 to 2.2) · 1,535 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 1.07 (0.76 to 1.38) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 214.59 (167.38 to 261.8) · 108 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 2.8 · 41 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 6 · 141 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 10.2 · 124 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 8.3 · 501 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 14.9 · 653 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 10.1 · 348 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 3 · 4,502 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.24 (0.04 to 0.43) · 9,014 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.34 (0.15 to 0.52) · 9,216 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 4.54 (2.51 to 6.58) · 1,421 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.54 (0 to 3.2) · 288 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.11 (0.66 to 3.56) · 1,446 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 11.61 (4.09 to 19.14) · 294 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 7.29 (3.39 to 11.2) · 299 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.9 (0.45 to 3.36) · 333 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.23 (0 to 0.78) · 7,538 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 5.4 · 94 cases | None | Apr 2023 – Mar 2025 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.735 | No different | Oct 2024 – Sep 2025 |
| SSI - Abdominal HysterectomyInfections | 2.573 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 14.6 · 185 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 22.1 · 951 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 56.3 · 128 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | 6.4 · 644 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 1.3 · 699 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 16.3 · 921 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 5.7 (3.9 to 8.1) · 226 cases | No different | Jan 2024 – Dec 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 12.6 (9.4 to 16.5) · 226 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.4 · 94 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 11.4 · 54 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 20.3 · 242 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 13.2 (9.9 to 17.4) · 702 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 1 (0.7 to 1.4) · 195 cases | No different | Jan 2024 – Dec 2024 |
What patients said (4,032 patients answered, 29% of those asked)
| Cleanliness | 3 |
| Nurse communication | 3 |
| Doctor communication | 3 |
| Communication about medicines | 3 |
| Discharge information | 2 |
| Overall hospital rating | 3 |
| Quietness | 2 |
| Recommend hospital | 4 |
| Room was "always" clean | 70% |
| Nurses "always" communicated well | 73% |
| Doctors "always" communicated well | 76% |
| Staff "always" explained | 57% |
| Yes, staff "did" give patients this information | 82% |
| Yes, staff "did" give patients information about help after discharge | 82% |
| Doctors "always" explained things so they could understand | 71% |
| Doctors "always" listened carefully | 74% |
| Doctors "always" treated them with courtesy and respect | 82% |
| Patients who gave a rating of "9" or "10" (high) | 67% |
| Staff "always" explained new medications | 71% |
| Nurses "always" explained things so they could understand | 71% |
| Nurses "always" listened carefully | 69% |
| Nurses "always" treated them with courtesy and respect | 80% |
| "Always" quiet at night | 43% |
| "YES", patients would definitely recommend the hospital | 70% |
| Staff "always" explained possible side effects | 44% |
| Yes, staff "did" give patients information about possible symptoms | 83% |
Original Medicare doctor bills
$72,047
Medicare paid this office $72,047 for 309 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Diagnostic exam of bladder and urethra using an endoscope | 119 | $28,509 | $219 |
| Short return visit (20+ min) | 92 | $7,825 | $77 |
| New patient visit (30+ min) | 50 | $4,757 | $95 |
| New patient visit (45+ min) | 25 | $3,652 | $146 |
| Return visit (30+ min) | 27 | $3,169 | $109 |
See all 8 services
| Diagnostic exam of bladder and urethra using an endoscope | 119 | $28,509 | $219 |
| Short return visit (20+ min) | 92 | $7,825 | $77 |
| New patient visit (30+ min) | 50 | $4,757 | $95 |
| New patient visit (45+ min) | 25 | $3,652 | $146 |
| Return visit (30+ min) | 27 | $3,169 | $109 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 12 | $1,271 | $106 |
| Short return visit | 11 | $578 | $53 |
| Urinalysis, manual test | 20 | $65 | $3 |
Who their Medicare patients are
309 Original Medicare patients in 2024. Average age 75 · Under 65 8% · 85 and older 18% · Women 38% · Also on Medicaid 38% · Health risk score 1.74. Above the middle of the specialty; the typical urology clinician is at 1.36.
Conditions among them: High blood pressure 75% · Diabetes 37% · Chronic kidney disease 35% · Cancer 27% · Coronary heart disease 26% · Atrial fibrillation 22% · COPD 21% · Depression 21% · Heart failure 19% · Dementia 12% · Stroke 10%.
The office billed $295,531, Medicare allowed $94,188 and paid $72,047; for 626 services of 41 kinds.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 309 | 626 | 75 | 1.74 | $295,531 | $72,047 |
| 2023 | 155 | 264 | 74 | 1.56 | $89,626 | $25,405 |
| 2022 | 24 | 43 | 78 | 1.93 | $7,764 | $2,124 |
| 2021 | 284 | 919 | 74 | 1.49 | $328,005 | $71,202 |
| 2020 | 602 | 2,507 | 74 | 1.56 | $867,044 | $182,493 |
| 2019 | 779 | 4,053 | 73 | 1.68 | $1,025,080 | $222,400 |
| 2018 | 644 | 2,575 | 73 | 1.56 | $834,368 | $173,246 |
| 2017 | 528 | 2,618 | 73 | 1.66 | $734,686 | $169,613 |
| 2016 | 367 | 2,423 | 74 | 1.43 | $314,005 | $61,986 |
| 2015 | 926 | 5,937 | 73 | 1.32 | $1,265,668 | $277,456 |
| 2014 | 694 | 3,703 | 72 | 1.29 | $1,016,301 | $243,256 |
| 2013 | 624 | 3,694 | 73 | 1.29 | $948,571 | $232,640 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 7 services
| Diagnostic exam of bladder and urethra using an endoscope | 49 | $11,337 | $231 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 25 | $1,739 | $60 |
| New patient visit (45+ min) | 12 | $1,649 | $137 |
| New patient visit (30+ min) | 12 | $1,220 | $102 |
| Short return visit (20+ min) | 13 | $1,073 | $83 |
| Short return visit | 17 | $891 | $52 |
| Initial hospital care with straightforward or low level of medical decision making, per day at least 40 minutes | 12 | $716 | $60 |
2022: 1 service
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 19 | $1,393 | $54 |
2021: 9 services
| Diagnostic exam of bladder and urethra using an endoscope | 71 | $13,398 | $181 |
| Return visit (30+ min) | 87 | $8,965 | $91 |
| Leuprolide acetate (for depot suspension), 7.5 mg | 11 | $8,455 | None |
| New patient visit (45+ min) | 55 | $6,991 | $127 |
| Short return visit (20+ min) | 110 | $6,195 | $53 |
| Ultrasound measurement of bladder capacity after voiding | 130 | $1,102 | $8 |
| New patient visit (30+ min) | 14 | $1,018 | $73 |
| Automated urinalysis test | 191 | $574 | $2 |
| Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle | 11 | $478 | $28 |
2020: 18 services
| Diagnostic exam of bladder and urethra using an endoscope | 186 | $37,148 | $170 |
| Leuprolide acetate (for depot suspension), 7.5 mg | 19 | $19,995 | None |
| New patient visit (45+ min) | 163 | $19,199 | $118 |
| Return visit (30+ min) | 192 | $18,913 | $81 |
| Short return visit (20+ min) | 198 | $13,379 | $57 |
| Shock wave crushing of kidney stones | 16 | $8,173 | $481 |
| Dilation of urethra using an endoscope | 19 | $5,287 | $278 |
| Destruction and/or removal of growth of bladder and urethra using an endoscope, 2.0-5.0 cm | 13 | $3,493 | $233 |
| New patient visit (30+ min) | 44 | $3,394 | $77 |
| Simple insertion of temporary bladder tube | 35 | $3,365 | $46 |
| Ultrasound measurement of bladder capacity after voiding | 320 | $3,325 | $8 |
| Ultrasound scan of pelvic region through rectum | 22 | $2,431 | $97 |
| Biopsy of prostate gland | 13 | $2,398 | $184 |
| Initial hospital care with straightforward or low level of medical decision making, per day at least 40 minutes | 23 | $2,108 | $84 |
| Telephone medical discussion with physician, 5-10 minutes | 51 | $1,973 | $36 |
| Complicated insertion of bladder tube | 13 | $1,466 | $98 |
| Automated urinalysis test | 399 | $1,381 | $2 |
| Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle | 19 | $1,006 | $27 |
2019: 21 services
| Diagnostic exam of bladder and urethra using an endoscope | 186 | $32,581 | $153 |
| New patient visit (45+ min) | 235 | $29,266 | $125 |
| Return visit (30+ min) | 253 | $25,405 | $82 |
| Leuprolide acetate (for depot suspension), 7.5 mg | 26 | $21,382 | None |
| Short return visit (20+ min) | 301 | $20,628 | $56 |
| Shock wave crushing of kidney stones | 13 | $8,060 | $474 |
| Ultrasound measurement of bladder capacity after voiding | 465 | $5,918 | $10 |
| New patient visit (30+ min) | 60 | $4,950 | $83 |
| Dilation of urethra using an endoscope | 18 | $4,292 | $238 |
| Biopsy of prostate gland | 18 | $3,587 | $199 |
| Initial hospital care with straightforward or low level of medical decision making, per day at least 40 minutes | 39 | $3,388 | $83 |
| Simple insertion of temporary bladder tube | 28 | $2,131 | $50 |
| Automated urinalysis test | 530 | $2,092 | $2 |
| Ultrasound scan of pelvic region through rectum | 22 | $1,886 | $75 |
| Complicated insertion of bladder tube | 13 | $1,683 | $112 |
| Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle | 27 | $1,085 | $26 |
| Diagnostic exam of bladder and urethra using an endoscope | 16 | $1,047 | $62 |
| New patient visit (15+ min) | 14 | $766 | $55 |
| Subsequent hospital care with straightforward or low level of medical decision making, per day at least 25 minutes | 14 | $452 | $30 |
| Office for the evaluation and management of established patient that may not require presence of healthcare professional | 20 | $406 | $19 |
| Ultrasonic guidance for needle placement | 14 | $266 | $19 |
2018: 20 services
| Return visit (30+ min) | 247 | $26,746 | $80 |
| Diagnostic exam of bladder and urethra using an endoscope | 177 | $24,574 | $131 |
| New patient visit (45+ min) | 178 | $21,020 | $118 |
| Short return visit (20+ min) | 207 | $13,190 | $52 |
| Leuprolide acetate (for depot suspension), 7.5 mg | 14 | $10,316 | None |
| Shock wave crushing of kidney stones | 19 | $9,428 | $449 |
| New patient visit (30+ min) | 82 | $6,143 | $75 |
| Biopsy of prostate gland | 26 | $5,094 | $176 |
| Ultrasound measurement of bladder capacity after voiding | 283 | $4,677 | $13 |
| Dilation of urethra using an endoscope | 19 | $4,205 | $221 |
| Destruction and/or removal of growth of bladder and urethra using an endoscope, 2.0-5.0 cm | 14 | $3,909 | $230 |
| Initial hospital care with straightforward or low level of medical decision making, per day at least 40 minutes | 43 | $3,337 | $78 |
| Destruction and/or removal of growth of bladder and urethra using an endoscope, 0.5-2.0 cm | 15 | $2,649 | $177 |
| Simple removal of foreign body, stone, or stent in urethra or bladder using an endoscope | 13 | $2,577 | $198 |
| Automated urinalysis test | 391 | $1,733 | $3 |
| Simple change of bladder tube | 12 | $1,132 | $67 |
| Ultrasound scan of pelvic region through rectum | 15 | $682 | $45 |
| Short return visit | 16 | $598 | $35 |
| Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle | 14 | $505 | $25 |
| Ultrasonic guidance for needle placement | 15 | $283 | $19 |
2017: 20 services
| New patient visit (45+ min) | 219 | $27,928 | $128 |
| Return visit (30+ min) | 195 | $23,440 | $85 |
| Diagnostic exam of bladder and urethra using an endoscope | 136 | $19,031 | $133 |
| Short return visit (20+ min) | 172 | $11,840 | $57 |
| Removal of prostate gland using an electrocautery knife through urethra with control of bleeding using an endoscope | 16 | $11,132 | $696 |
| Leuprolide acetate (for depot suspension), 7.5 mg | 15 | $9,801 | None |
| New patient visit (30+ min) | 120 | $9,264 | $77 |
| Shock wave crushing of kidney stones | 12 | $6,555 | $468 |
| Crushing of stone of ureter using an endoscope | 13 | $4,508 | $322 |
| Dilation of urethra using an endoscope | 19 | $4,329 | $228 |
| Ultrasound measurement of bladder capacity after voiding | 185 | $3,692 | $16 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 30 | $3,542 | $111 |
| Biopsy of prostate gland | 11 | $2,219 | $202 |
| Simple insertion of temporary bladder tube | 26 | $2,190 | $51 |
| Automated urinalysis test | 306 | $1,457 | $3 |
| Ultrasound scan of pelvic region through rectum | 27 | $1,431 | $51 |
| New patient visit (15+ min) | 13 | $800 | $62 |
| Insertion of temporary bladder tube | 17 | $670 | $39 |
| Ultrasonic guidance for needle placement | 27 | $644 | $23 |
| Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle | 16 | $602 | $27 |
2016: 11 services
| Return visit (30+ min) | 157 | $9,339 | $57 |
| Diagnostic exam of bladder and urethra using an endoscope | 72 | $7,022 | $95 |
| New patient visit (45+ min) | 47 | $4,929 | $105 |
| Complex measurement of pressure of urine flow in bladder with voiding pressure studies | 15 | $3,160 | $211 |
| Short return visit (20+ min) | 68 | $2,579 | $37 |
| New patient visit (30+ min) | 28 | $2,342 | $84 |
| Ultrasound measurement of bladder capacity after voiding | 138 | $1,692 | $12 |
| Insertion of device into abdomen with pressure and urine flow rate study | 13 | $1,077 | $83 |
| Injection procedure for imaging of bladder during voiding | 12 | $872 | $73 |
| Urinalysis, manual test | 191 | $741 | $3 |
| Automated urinalysis test | 46 | $168 | $3 |
2015: 27 services
| Return visit (30+ min) | 489 | $50,465 | $74 |
| Diagnostic exam of bladder and urethra using an endoscope | 292 | $28,633 | $93 |
| New patient visit (45+ min) | 246 | $27,037 | $110 |
| Shock wave crushing of kidney stones | 32 | $17,672 | $421 |
| Short return visit (20+ min) | 236 | $13,735 | $51 |
| Removal of prostate gland using an electrocautery knife through urethra with control of bleeding using an endoscope | 21 | $13,370 | $637 |
| Dilation of urethra using an endoscope | 92 | $10,330 | $108 |
| Ultrasound measurement of bladder capacity after voiding | 474 | $7,920 | $13 |
| Creation of sling around urethra in female to control leakage | 14 | $7,411 | $529 |
| Complex measurement of pressure of urine flow in bladder with voiding pressure studies | 33 | $7,239 | $219 |
| Removal or manipulation of stone in ureter or kidney using an endoscope | 20 | $6,155 | $256 |
| Destruction and/or removal of growth of bladder and urethra using an endoscope, 2.0-5.0 cm | 14 | $4,659 | $222 |
| Initial hospital care with straightforward or low level of medical decision making, per day at least 40 minutes | 54 | $4,307 | $76 |
| Urinalysis, manual test | 686 | $3,795 | $3 |
| Insertion of device into abdomen with pressure and urine flow rate study | 32 | $2,654 | $83 |
| Destruction and/or removal of growth of bladder and urethra using an endoscope, 0.5-2.0 cm | 11 | $2,458 | $189 |
| Injection procedure for imaging of bladder during voiding | 32 | $2,172 | $68 |
| Insertion of stent in ureter using an endoscope | 20 | $1,991 | $80 |
| Simple removal of foreign body, stone, or stent in urethra or bladder using an endoscope | 14 | $1,746 | $109 |
| New patient visit (30+ min) | 23 | $1,735 | $75 |
| Simple insertion of temporary bladder tube | 14 | $1,143 | $50 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 12 | $1,126 | $94 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 13 | $936 | $55 |
| Review by radiologist of urinary bladder and urethra images with contrast and after passing urine | 15 | $891 | $59 |
| Electronic analysis of implanted neurostimulator generator with complex spinal cord or peripheral nerve stimulator programming | 12 | $581 | $42 |
| Electronic analysis of implanted brain, spinal cord, or peripheral neurostimulator generator | 11 | $411 | $37 |
| Electronic assessment of bladder emptying | 32 | $190 | $6 |
2014: 23 services
| Return visit (30+ min) | 385 | $42,413 | $72 |
| New patient visit (45+ min) | 242 | $27,244 | $113 |
| Diagnostic exam of bladder and urethra using an endoscope | 179 | $17,748 | $94 |
| Short return visit (20+ min) | 238 | $14,802 | $51 |
| Shock wave crushing of kidney stones | 18 | $9,414 | $409 |
| Dilation of urethra using an endoscope | 57 | $6,537 | $111 |
| Ultrasound measurement of bladder capacity after voiding | 359 | $6,468 | $13 |
| Complex measurement of pressure of urine flow in bladder with voiding pressure studies | 29 | $6,412 | $214 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 49 | $5,206 | $104 |
| Removal or manipulation of stone in ureter or kidney using an endoscope | 14 | $4,010 | $267 |
| Urinalysis, manual test | 538 | $3,667 | $3 |
| Insertion of device into abdomen with pressure and urine flow rate study | 29 | $2,453 | $82 |
| Initial hospital care with straightforward or low level of medical decision making, per day at least 40 minutes | 28 | $2,143 | $77 |
| Injection procedure for imaging of bladder during voiding | 29 | $2,129 | $71 |
| Review by radiologist of urinary bladder and urethra images with contrast and after passing urine | 29 | $1,865 | $62 |
| Insertion of stent in ureter using an endoscope | 15 | $1,545 | $97 |
| Initial hospital observation care per day, typically 50 minutes | 14 | $1,438 | $103 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 18 | $1,203 | $55 |
| Electronic analysis of implanted brain, spinal cord, or peripheral neurostimulator generator | 15 | $897 | $50 |
| Insertion or replacement of peripheral, sacral, or gastric neurostimulator generator or receiver | 11 | $883 | $80 |
| New patient visit (30+ min) | 12 | $850 | $71 |
| Injection of drug or substance under skin or into muscle | 12 | $276 | $18 |
| Electronic assessment of bladder emptying | 29 | $180 | $6 |
2013: 20 services
| Return visit (30+ min) | 376 | $46,982 | $74 |
| New patient visit (45+ min) | 230 | $25,726 | $112 |
| Leuprolide acetate (for depot suspension), 7.5 mg | 14 | $19,274 | None |
| Diagnostic exam of bladder and urethra using an endoscope | 169 | $16,575 | $93 |
| Short return visit (20+ min) | 222 | $14,317 | $50 |
| Ultrasound measurement of bladder capacity after voiding | 345 | $6,568 | $14 |
| Complex measurement of pressure of urine flow in bladder with voiding pressure studies | 26 | $6,094 | $234 |
| Dilation of urethra using an endoscope | 54 | $6,002 | $103 |
| Urinalysis, manual test | 500 | $3,621 | $3 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 26 | $2,635 | $101 |
| New patient visit (30+ min) | 37 | $2,585 | $70 |
| Insertion of device into abdomen with pressure and urine flow rate study | 25 | $2,093 | $84 |
| Injection procedure for imaging of bladder during voiding | 27 | $1,897 | $70 |
| Insertion of stent in ureter using an endoscope | 20 | $1,708 | $85 |
| Review by radiologist of urinary bladder and urethra images with contrast and after passing urine | 23 | $1,462 | $64 |
| Initial hospital care with straightforward or low level of medical decision making, per day at least 40 minutes | 17 | $1,200 | $71 |
| Simple insertion of temporary bladder tube | 11 | $962 | $42 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 11 | $744 | $53 |
| Injection of drug or substance under skin or into muscle | 12 | $571 | $18 |
| Electronic assessment of bladder emptying | 26 | $156 | $6 |
Medicaid work
$1,174 in 2024
Medicaid paid $1,174 for 14 billed services this clinician did in 2024, up to 14 people in a month for one service.
Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.
| CYSTOURETHROSCOPY | 14 | $1,174 |
| 2024 | 14 | 1 | 14 | $1,174 |
| 2020 | 13 | 1 | 12 | $20 |
See the largest Medicaid services in earlier years
2020
| Urinalysis, by dip stick or tablet reagent for bilirubin, glucose, hemoglobin, ketones, leukocytes, nitrite, pH, protein, specific gravity, urobilinogen, any number of these constituents; automated, without microscopy | 13 | $20 |
Drugs they prescribed that Part D paid
$33,907
Pharmacies billed $33,907 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
450 generic and 29 brand-name prescriptions · $33,907 in drug cost · 22 antibiotic prescriptions to 21 people.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Myrbetriq | 25 | $20,568 | $823 |
| Estradiol | 45 | $3,781 | $84 |
| Solifenacin | 37 | $3,216 | $87 |
| Tamsulosin | 163 | $2,346 | $14 |
| Oxybutynin Chloride Er | 34 | $826 | $24 |
See all 10 drugs
| Myrbetriq | 25 | $20,568 | $823 |
| Estradiol | 45 | $3,781 | $84 |
| Solifenacin | 37 | $3,216 | $87 |
| Tamsulosin | 163 | $2,346 | $14 |
| Oxybutynin Chloride Er | 34 | $826 | $24 |
| Oxybutynin Chloride | 27 | $501 | $19 |
| Dutasteride | 26 | $317 | $12 |
| Midodrine | 30 | $285 | $9 |
| Alfuzosin Hcl Er | 13 | $242 | $19 |
| Finasteride | 19 | $160 | $8 |
Year by year
| 2024 | 479 | 144 | None | 6% | $33,907 |
| 2023 | 59 | 46 | 0% (0) | None | $6,251 |
| 2022 | 116 | 50 | None | 13% | $12,224 |
| 2021 | 893 | 291 | 1% (11) | 14% | $103,184 |
| 2020 | 1,553 | 444 | 2% (32) | 12% | $156,517 |
| 2019 | 1,352 | 441 | 3% (39) | None | $132,363 |
| 2018 | 1,174 | 385 | 4% (48) | None | $126,786 |
| 2017 | 1,173 | 395 | 3% (35) | 17% | $100,776 |
| 2016 | 1,212 | 377 | 2% (26) | 24% | $123,590 |
| 2015 | 2,705 | 643 | 4% (107) | 26% | $226,745 |
| 2014 | 2,468 | 540 | 5% (112) | 22% | $165,336 |
| 2013 | 2,399 | 493 | 4% (89) | 19% | $138,014 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 2 drugs
| Estradiol | 11 | $1,568 | $143 |
| Tamsulosin | 17 | $688 | $40 |
2022: 4 drugs
| Myrbetriq | 11 | $5,693 | $518 |
| Oxybutynin Chloride Er | 23 | $787 | $34 |
| Tamsulosin | 29 | $584 | $20 |
| Potassium Citrate Er | 11 | $548 | $50 |
2021: 10 drugs
| Myrbetriq | 79 | $45,404 | $575 |
| Premarin | 37 | $15,611 | $422 |
| Oxybutynin Chloride Er | 230 | $12,943 | $56 |
| Estradiol | 98 | $12,114 | $124 |
| Tamsulosin | 200 | $5,188 | $26 |
| Oxybutynin Chloride | 54 | $1,459 | $27 |
| Finasteride | 30 | $807 | $27 |
| Nitrofurantoin Mono-Macro | 23 | $799 | $35 |
| Cephalexin | 17 | $284 | $17 |
| Sulfamethoxazole-Trimethoprim | 52 | $213 | $4 |
2020: 15 drugs
| Myrbetriq | 84 | $50,908 | $606 |
| Premarin | 76 | $32,821 | $432 |
| Oxybutynin Chloride Er | 341 | $17,866 | $52 |
| Tamsulosin | 411 | $11,952 | $29 |
| Estradiol | 62 | $11,893 | $192 |
| Estrace | 23 | $8,194 | $356 |
| Oxybutynin Chloride | 71 | $3,010 | $42 |
| Nitrofurantoin Mono-Macro | 54 | $1,690 | $31 |
| Finasteride | 78 | $1,370 | $18 |
| Cephalexin | 49 | $707 | $14 |
| Sulfamethoxazole-Trimethoprim | 84 | $391 | $5 |
| Allopurinol | 12 | $361 | $30 |
| Hydrocodone-Acetaminophen | 31 | $263 | $8 |
| Ciprofloxacin | 57 | $244 | $4 |
| Nystatin | 14 | $151 | $11 |
2019: 15 drugs
| Myrbetriq | 74 | $41,369 | $559 |
| Premarin | 103 | $41,184 | $400 |
| Oxybutynin Chloride Er | 276 | $14,187 | $51 |
| Tamsulosin | 381 | $11,761 | $31 |
| Oxybutynin Chloride | 49 | $2,990 | $61 |
| Estradiol | 11 | $2,211 | $201 |
| Potassium Citrate Er | 15 | $1,299 | $87 |
| Nitrofurantoin Mono-Macro | 38 | $1,101 | $29 |
| Cephalexin | 59 | $882 | $15 |
| Finasteride | 44 | $692 | $16 |
| Sulfamethoxazole-Trimethoprim | 70 | $619 | $9 |
| Bicalutamide | 11 | $479 | $44 |
| Allopurinol | 17 | $397 | $23 |
| Hydrocodone-Acetaminophen | 36 | $349 | $10 |
| Ciprofloxacin | 53 | $239 | $5 |
2018: 14 drugs
| Premarin | 100 | $39,448 | $394 |
| Myrbetriq | 69 | $28,680 | $416 |
| Tamsulosin | 369 | $14,381 | $39 |
| Oxybutynin Chloride Er | 153 | $9,368 | $61 |
| Oxybutynin Chloride | 81 | $4,571 | $56 |
| Estradiol | 12 | $2,668 | $222 |
| Nitrofurantoin Mono-Macro | 37 | $1,799 | $49 |
| Finasteride | 57 | $963 | $17 |
| Desmopressin Acetate | 14 | $955 | $68 |
| Nitrofurantoin | 13 | $879 | $68 |
| Cephalexin | 38 | $629 | $17 |
| Hydrocodone-Acetaminophen | 46 | $426 | $9 |
| Sulfamethoxazole-Trimethoprim | 37 | $327 | $9 |
| Ciprofloxacin | 45 | $177 | $4 |
2017: 15 drugs
| Premarin | 90 | $32,068 | $356 |
| Myrbetriq | 38 | $16,497 | $434 |
| Tamsulosin | 313 | $13,473 | $43 |
| Oxybutynin Chloride Er | 152 | $8,572 | $56 |
| Vesicare | 11 | $7,312 | $665 |
| Oxybutynin Chloride | 121 | $6,330 | $52 |
| Nitrofurantoin Mono-Macro | 49 | $2,206 | $45 |
| Finasteride | 66 | $1,101 | $17 |
| Sulfamethoxazole-Trimethoprim | 67 | $413 | $6 |
| Imipramine | 16 | $263 | $16 |
| Ciprofloxacin | 39 | $181 | $5 |
| Amitriptyline | 13 | $165 | $13 |
| Hydrocodone-Acetaminophen | 26 | $134 | $5 |
| Cephalexin | 17 | $128 | $8 |
| Losartan | 12 | $65 | $5 |
2016: 22 drugs
| Myrbetriq | 100 | $33,127 | $331 |
| Premarin | 67 | $20,298 | $303 |
| Oxybutynin Chloride | 236 | $7,851 | $33 |
| Toviaz | 16 | $6,668 | $417 |
| Tolterodine Tartrate Er | 25 | $6,051 | $242 |
| Vagifem | 15 | $5,975 | $398 |
| Tamsulosin | 212 | $5,953 | $28 |
| Estrace | 21 | $5,675 | $270 |
| Estring | 17 | $5,476 | $322 |
| Oxybutynin Chloride Er | 50 | $3,693 | $74 |
| Nitrofurantoin Mono-Macro | 46 | $2,289 | $50 |
| Tolterodine | 17 | $1,990 | $117 |
| Nitrofurantoin | 34 | $1,010 | $30 |
| Finasteride | 54 | $630 | $12 |
| Prazosin | 13 | $459 | $35 |
| Doxazosin Mesylate | 12 | $406 | $34 |
| Sulfamethoxazole-Trimethoprim | 58 | $375 | $6 |
| Allopurinol | 27 | $359 | $13 |
| Ciprofloxacin | 58 | $297 | $5 |
| Hydrocodone-Acetaminophen | 23 | $262 | $11 |
| Cephalexin | 15 | $95 | $6 |
| Glimepiride | 12 | $85 | $7 |
2015: 33 drugs
| Premarin | 161 | $44,065 | $274 |
| Myrbetriq | 93 | $29,694 | $319 |
| Vesicare | 61 | $18,682 | $306 |
| Estrace | 77 | $16,581 | $215 |
| Vagifem | 63 | $15,016 | $238 |
| Oxybutynin Chloride | 431 | $14,130 | $33 |
| Tamsulosin | 338 | $12,491 | $37 |
| Oxybutynin Chloride Er | 113 | $9,243 | $82 |
| Estring | 31 | $8,371 | $270 |
| Tolterodine | 57 | $8,363 | $147 |
| Nitrofurantoin Mono-Macro | 181 | $8,241 | $46 |
| Toviaz | 22 | $6,743 | $307 |
| Tolterodine Tartrate Er | 27 | $6,406 | $237 |
| Rapaflo | 17 | $4,310 | $254 |
| Nitrofurantoin | 83 | $1,989 | $24 |
| Ciprofloxacin | 250 | $1,115 | $4 |
| Hydrocodone-Acetaminophen | 94 | $977 | $10 |
| Sulfamethoxazole-Trimethoprim | 144 | $944 | $7 |
| Phenazopyridine | 29 | $901 | $31 |
| Doxycycline Hyclate | 11 | $842 | $77 |
| Doxazosin Mesylate | 26 | $816 | $31 |
| Piroxicam | 11 | $744 | $68 |
| Desmopressin Acetate | 15 | $618 | $41 |
| Allopurinol | 26 | $554 | $21 |
| Finasteride | 28 | $487 | $17 |
| Cephalexin | 61 | $453 | $7 |
| Alfuzosin Hcl Er | 13 | $246 | $19 |
| Ampicillin Trihydrate | 39 | $229 | $6 |
| Imipramine | 12 | $219 | $18 |
| Fluconazole | 16 | $164 | $10 |
| Hydrochlorothiazide | 19 | $90 | $5 |
| Glimepiride | 11 | $50 | $5 |
| Amlodipine Besylate | 12 | $28 | $2 |
2014: 27 drugs
| Estrace | 128 | $21,014 | $164 |
| Myrbetriq | 50 | $17,788 | $356 |
| Premarin | 74 | $16,554 | $224 |
| Oxybutynin Chloride | 461 | $16,332 | $35 |
| Vesicare | 67 | $14,508 | $217 |
| Vagifem | 61 | $11,343 | $186 |
| Estring | 44 | $10,299 | $234 |
| Oxybutynin Chloride Er | 107 | $8,957 | $84 |
| Tamsulosin | 299 | $7,606 | $25 |
| Nitrofurantoin Mono-Macro | 104 | $5,218 | $50 |
| Toviaz | 22 | $5,216 | $237 |
| Avodart | 21 | $4,027 | $192 |
| Tolterodine | 26 | $3,845 | $148 |
| Nitrofurantoin | 104 | $3,225 | $31 |
| Rapaflo | 17 | $3,170 | $186 |
| Enablex | 13 | $3,054 | $235 |
| Desmopressin Acetate | 15 | $1,260 | $84 |
| Ciprofloxacin | 264 | $1,238 | $5 |
| Hydrocodone-Acetaminophen | 101 | $912 | $9 |
| Sulfamethoxazole-Trimethoprim | 99 | $666 | $7 |
| Cephalexin | 70 | $516 | $7 |
| Ampicillin Trihydrate | 56 | $341 | $6 |
| Allopurinol | 42 | $328 | $8 |
| Doxazosin Mesylate | 14 | $223 | $16 |
| Fluconazole | 13 | $149 | $11 |
| Levofloxacin | 14 | $127 | $9 |
| Megestrol Acetate | 22 | $122 | $6 |
2013: 30 drugs
| Vesicare | 93 | $19,787 | $213 |
| Estrace | 110 | $15,806 | $144 |
| Premarin | 80 | $15,391 | $192 |
| Vagifem | 60 | $11,685 | $195 |
| Oxybutynin Chloride Er | 90 | $9,199 | $102 |
| Tamsulosin | 323 | $7,768 | $24 |
| Estring | 35 | $7,569 | $216 |
| Oxybutynin Chloride | 416 | $7,230 | $17 |
| Nitrofurantoin Mono-Macro | 122 | $6,671 | $55 |
| Myrbetriq | 17 | $6,263 | $368 |
| Rapaflo | 30 | $4,275 | $143 |
| Avodart | 23 | $3,976 | $173 |
| Toviaz | 18 | $3,641 | $202 |
| Enablex | 12 | $3,421 | $285 |
| Nitrofurantoin | 55 | $1,957 | $36 |
| Ciprofloxacin | 356 | $1,458 | $4 |
| Sulfamethoxazole-Trimethoprim | 122 | $884 | $7 |
| Desmopressin Acetate | 14 | $515 | $37 |
| Hydrocodone-Acetaminophen | 74 | $452 | $6 |
| Imipramine | 16 | $383 | $24 |
| Ampicillin Trihydrate | 53 | $321 | $6 |
| Doxazosin Mesylate | 23 | $317 | $14 |
| Bicalutamide | 13 | $309 | $24 |
| Cephalexin | 33 | $255 | $8 |
| Megestrol Acetate | 28 | $173 | $6 |
| Allopurinol | 25 | $171 | $7 |
| Fluconazole | 11 | $130 | $12 |
| Tramadol | 13 | $129 | $10 |
| Levofloxacin | 12 | $90 | $7 |
| Phenazopyridine | 14 | $72 | $5 |
Money from drug and device companies
$102 in 2025
| 2025 | 4 | 5 | None | $102 |
| 2024 | 8 | 14 | None | $336 |
| 2023 | 5 | 8 | None | $392 |
| 2022 | 1 | 4 | None | $203 |
| 2021 | 1 | 4 | None | $216 |
| 2020 | 3 | 5 | None | $311 |
| 2019 | 3 | 5 | None | $276 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| United Therapeutics | Tyvaso | $47 | 2 payments
|
| Baxter Healthcare | Hillrom - Monarch Airway Clearance System | $20 | 1 payment
|
| Verona Pharma | Ohtuvayre | $19 | 1 payment
|
| Urogen Pharma | Zusduri | $17 | 1 payment
|
See all 5 published payments
| United Therapeutics | Meals · 2025-12-15 | Tyvaso | $30 |
| Urogen Pharma | Meals · 2025-11-14 | Zusduri | $17 |
| Baxter Healthcare | Meals · 2025-11-13 | Hillrom - Monarch Airway Clearance System | $20 |
| United Therapeutics | Meals · 2025-10-30 | Tyvaso | $17 |
| Verona Pharma | Meals · 2025-10-28 | Ohtuvayre | $19 |
See earlier years (2024, 2023, 2022, 2021, 2020, 2019)
2024: $336
| Janssen Biotech | Erleada | $65 | 3 payments
|
| Actelion Pharmaceuticals US | Opsumit | $64 | 3 payments
|
| United Therapeutics | Tyvaso | $56 | 2 payments
|
| Myriad Genetic Laboratories | Prolaris | $44 | 2 payments
|
| Laborie Medical Technologies | Optilume Bph Drug Coated Balloon Catheter | $44 | 1 payment
|
| GlaxoSmithKline | Trelegy Ellipta | $25 | 1 payment
|
| Regeneron Healthcare Solutions | Dupixent | $21 | 1 payment
|
| Boston Scientific | Lithovue | $17 | 1 payment
|
2023: $392
| Janssen Biotech | Erleada | $153 | 2 payments
|
| Myriad Genetic Laboratories | Prolaris | $124 | 2 payments
|
| Axonics | Axonics | $50 | 1 payment
|
| CSL Behring | Kcentra | $40 | 2 payments
|
| Pfizer | Xtandi | $25 | 1 payment
|
2022: $203
| Axonics | Axonics | $203 | 4 payments
|
2021: $216
| Axonics | Axonics R-Snm System | $216 | 4 payments
|
2020: $311
| Axonics Modulation Technologies | Axonics R-Snm System | $218 | 3 payments
|
| Astellas Pharma US | Xtandi | $75 | 1 payment
|
| Myriad Genetic Laboratories | Bracanalysis Cdx | $19 | 1 payment
|
2019: $276
| Astellas Pharma US | Xtandi | $129 | 2 payments
|
| Janssen Biotech | Erleada | $96 | 1 payment
|
| Boston Scientific | Rezum | $51 | 2 payments
|
Checkups this office reported
Medicare did not publish checkup rates for this clinician.
- Medicare’s overall office score
- 88.0 / 100
- Scores the office’s reporting and systems. It is not a grade for how the doctor treats you.
Professional record
- NPI
- 1467463422
- Licence
- CA G144001, IN 01065467A, MI AS056566California G144001: Current · expires 2028-03-31
- Trained
- University of Michigan Medical School, 1990
- Group
- Northbay Physicians Surgery Center, LLC · Northbay Health Medical Foundation · County of Santa Clara
- Gender
- Female
More record details
- Sole proprietor
- No
- Medicaid ID
- IN 200907330, MI 3193742
- Taxonomy
- Urology (208800000X)
- Mailing address
- 600 Coffee Rd, Modesto, CA, 95355
- NPI first listed
- 2006-08-11
- NPI last updated
- 2016-11-17
This is when the NPI record was last certified, not a medical board exam.